Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients.

ABSTRACT:

Objectives

To evaluate the impact of the CYP4F2 polymorphism on bleeding complications and over-anticoagulation due to coumarin.

Methods

A comprehensive literature search was performed to look for eligible studies published prior to February 2015 in EMBASE and PubMed. References were strictly identified by inclusion and exclusion criteria, and authors of primary studies were consulted for additional information and data. Revman 5.3 software was used to analyze the impact of the CYP4F2 polymorphism on hemorrhagic complications and over-anticoagulation events (international normalized ratio greater than 4).

Results

Eight studies involving 3,101 samples met the specified inclusion criteria. Compared with wild-type homozygotes (CYP4F2*1*1), carriers of the CYP4F2*3 varian

SUBMITTER: Chen P 

PROVIDER: S-EPMC4852013 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature